Literature DB >> 31147848

Cerebral Venous Thrombosis Headache.

Amit Mehta1, Julius Danesh2, Deena Kuruvilla2.   

Abstract

PURPOSE OF REVIEW: Cerebral venous thrombosis (CVT) is a neurovascular disease caused by a thrombotic occlusion of either a dural sinus or cerebral vein. CVT results in a variety of neurological symptoms with the most common being headache. The purpose of this review is to characterize CVT, describe the headache pattern, and, finally, provide an update to date review of diagnostic and treatment options for this condition. RECENT
FINDINGS: CVT is a very difficult disease to diagnose due to the variability in both patient presentation and imaging findings. Recent literature has attempted to standardize its risk factors, diagnosis, and treatment modalities. Additionally, new laboratory studies are being investigated for CVT patients who present with isolated headaches. CVT is a debilitating disease requiring immediate medical or surgical intervention. Because the disease can mask as a multitude of neurological deficits, patients are not properly diagnosed. Headache is the most common patient presentation. The quality of this headache is highly variable with no specific location or pattern. New literature has provided insight into potential diagnostic and treatment options for CVT patients. However, further large-scale cohort studies are necessary to standardize the care for this disease.

Entities:  

Keywords:  Cerebral venous thrombosis; Cerebral venous thrombosis headache; Thrombosis, isolated headache, headache in young; Thunderclap headache

Year:  2019        PMID: 31147848     DOI: 10.1007/s11916-019-0786-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  10 in total

1.  [Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination].

Authors: 
Journal:  Neurologia       Date:  2021-05-06       Impact factor: 3.109

Review 2.  Headache in cerebrovascular diseases.

Authors:  Jiajie Lu; Wei Liu; Hongru Zhao
Journal:  Stroke Vasc Neurol       Date:  2020-03-26

Review 3.  Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions.

Authors:  Nicoletta Riva; Walter Ageno
Journal:  J Clin Med       Date:  2020-03-10       Impact factor: 4.241

4.  Effects of Astragalus Polysaccharides Nanoparticles on Cerebral Thrombosis in SD Rats.

Authors:  Qian Sun; Pengqiang Shi; Cuiling Lin; Jing Ma
Journal:  Front Bioeng Biotechnol       Date:  2020-12-23

5.  Cerebral Venous Thrombosis Presenting as a Subacute Headache in a Young Man With Undiagnosed Factor V Leiden Mutation.

Authors:  Tanvi H Patel; Ramya Bachu; Jennifer E Naylor; Gerry Ezell
Journal:  Cureus       Date:  2021-04-24

6.  Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental?

Authors:  Khezar Syed; Haseeb Chaudhary; Anthony Donato
Journal:  Am J Case Rep       Date:  2021-09-03

Review 7.  microRNAs in Subarachnoid Hemorrhage (Review of Literature).

Authors:  Marianna Makowska; Beata Smolarz; Hanna Romanowicz
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

8.  Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination.

Authors: 
Journal:  Neurologia (Engl Ed)       Date:  2021-05-29

9.  Presence of red flags in patients with cerebral venous sinus thrombosis admitted to the emergency department because of headache: A STROBE compliant cohort-study.

Authors:  David García-Azorín; Mariana H G Monje; Nuria González-García; Ángel L Guerrero; Jesús Porta-Etessam
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

10.  [Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination].

Authors: 
Journal:  Neurologia       Date:  2021-05-06       Impact factor: 3.109

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.